76 reports

  • Vendor landscape
  • ASTRAZENECA

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 9 Appendix

GASTROINTESTINAL EVENTS SUCH AS NAUSEA AND DIARRHEA OCCURRED MOST FREQUENTLY.

  • Type 2 Diabetes
  • Asia
  • World
  • Novo Nordisk Group
  • Sanofi S.A.
  • 7.1 OVERVIEW

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Type 2 Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Trial Results

GASTROINTESTINAL, AUTOIMMUNE DISEASE HISTORY OF MALIGNANCY, DRUG OR ALCOHOL ABUSE PARTICIPATION IN ANY PREVIOUS TRIAL ON ACE INHIBITOR TAKING OTHER INVESTIGATIONAL DRUGS WITHIN THE PAST ## DAYS KNOWN HISTORY OF SENSITIVITY / ALLERGY TO ACE INHIBITOR EXPECTED SURVIVAL LESS THAN ## YEARS

  • Type 2 Diabetes
  • World
  • Anthera Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Novartis AG

The combined portfolio of the two companies includes drugs in areas of dermatology, CNS, eye care, women' s health, urology, gastrointestinal, cystic fibrosis, cardiovascular, and infectious diseases.

  • Type 2 Diabetes
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG

THE ENDOBARRIER GASTROINTESTINAL LINER IS TRANSORALLY PLACED IN THE GASTROINTESTINAL TRACT IN ORDER TO BYPASS A PORTION OF THE INTESTINE.

  • Type 2 Diabetes
  • United States
  • EnteroMedics Inc.
  • Novo Nordisk Group
  • VIVUS, Inc.

PATIENTS IN THE STANDARD CARE GROUP DEVELOPED CELLULITIS OF THE EFFECTED EXTREMITY (TWO PATIENTS), A GASTROINTESTINAL BLEED (ONE PATIENT), AND ACUTE PYELONEPHRITIS (ONE PATIENT).

  • Type 2 Diabetes
  • Japan
  • FirstString Research, Inc.
  • Organogenesis, Inc.
  • Smith & Nephew Plc

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • RDX-98940 - Drug Profile
  • Pipeline by Ardelyx Inc, H2 2017

The drug candidate is an agonist of TGR##, a G protein-coupled receptor found in the gastrointestinal (GI) tract.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

GASTROINTESTINAL AND METABOLIC DISORDERS - DRUG PROFILE FGH-## - DRUG PROFILE KR-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description KR-## NA NA Korea Research Institute of Chemical Technology R& D Progress Resear

  • Diabetes
  • Type 2 Diabetes
  • World
  • Product Initiative
  • PhaseBio Pharmaceuticals, Inc.
  • PIPELINE BY ELI LILLY AND COMPANY, H2 2017

Hanmi Pharma" s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Molecular Diagnostic
  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative

Hyperglycemia - Pipeline Review, H## 2017 Reference Code: GMDHC##IDB Publication Date: June 2017 Introduction Global Markets Direct Report Coverage Global Markets Direct' s, ' Hyperglycemia - Pipeline Review, H## 2017', provides an overview of the Hyperglycemia pipeline landscape.

  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Mitsubishi Corporation

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Molecular Diagnostic
  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative

Pharmaceuticals & Healthcare - Deals and Alliances Profile Poxel SA (POXEL) October 2017 Report Code: GDPH##D Published: Company Snapshot Company Overview Key Facts Poxel SA (Poxel) is a biopharmaceutical company that develops and markets drugs for metabolic diseases.

  • Diabetes
  • Type 2 Diabetes
  • Japan
  • Company
  • POXEL SA
  • Jun 19, 2017: GI Dynamics Announces Additional Members to Its Scientific Advisory Board
  • Deal Information Deal Status Completed Date Deal Financials

His clinical areas of expertise include laparoscopic and gastrointestinal surgery.

  • Healthcare
  • Type 2 Diabetes
  • United States
  • Company
  • GI Dynamics

Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Genito Urinary System And Sex Hormones, Gastrointestinal, Immunology, Oncology, Respiratory and Undisclosed which include indications Diabetic Complications, Diabetic Nephropathy, Acute Ischemic Stroke, Atheroscl

  • Chronic Disease
  • Diabetes
  • Therapy
  • Type 2 Diabetes
  • GenKyoTex S.A.

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Endocrine Disease
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Boehringer Ingelheim GmbH
  • APR 02, 2016: SEMAGLUTIDE DEMONSTRATED SUPERIOR IMPROVEMENTS IN GLYCAEMIC CONTROL VS PLACEBO IN ADULTS WITH TYPE 2 DIABETES
  • 09/15/2016: VICTOZA LOWERED THE PROGRESSION OF KIDNEY DAMAGE IN ADULTS WITH TYPE 2 DIABETES AT HIGH CV RISK

The most common adverse events leading to the discontinuation of Victoza® were gastrointestinal events.

  • Diabetes
  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Novo Nordisk Group

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Endocrine Disease
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Boehringer Ingelheim GmbH
  • JAN 21, 2016: VTV THERAPEUTICS INITIATES PHASE 2 TRIAL EVALUATING TTP273 FOR THE TREATMENT OF TYPE 2 DIABETES

In this study, all doses of TTP## were well tolerated with no serious adverse events or evidence of significant gastrointestinal side effects.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company Operations
  • vTv Therapeutics LLC
  • RDX-98940 - Drug Profile

It discovers, develops and commercializes small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY GILEAD SCIENCES INC, H2 2017
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY GNI GROUP LTD, H2 2017

No grade ## gastrointestinal adverse events were reported.

  • Chronic Disease
  • Genitourinary System Disease
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • Type 2 Diabetes Mellitus, Global, Pipeline Size by Therapy Area, 2016
  • Type 2 Diabetes Mellitus, Global, Deal Involvement of First-in-Class Programs, 2016 (part 3)

Bile acid sequestrants such as Welchol (colesevelam) are a group of resins used to bind certain components of bile in the gastrointestinal tract.

  • Chronic Disease
  • Insulin
  • Pathology
  • Type 2 Diabetes
  • World

Report covers products from therapy areas Metabolic Disorders, Undisclosed and Gastrointestinal which include indications Diabetes, Type ## Diabetes, Unspecified, Non Alcoholic Fatty Liver Disease (NAFLD) and Non- Alcoholic Steatohepatitis (NASH).

  • Molecular Diagnostic
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • GlaxoSmithKline plc

The company' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Cholesterol
  • Type 2 Diabetes
  • South Korea
  • United States
  • World
  • May 04, 2017: Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor

The most common side effects were mild gastrointestinal issues, which were comparable between the ZGN-## and placebo groups, headache and procedural related irritation.

  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • Zafgen, Inc.
  • BARDOXOLONE METHYL - DRUG PROFILE

Gastrointestinal events were the frequent adverse event leading to withdrawal during XP## treatment.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • RPI
  • 7 Business Operation Structure
  • Telotristatetiprate (LX1032)

SGLT## is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract.

  • Diabetes
  • Endocrine Disease
  • Pharmaceutical
  • Type 2 Diabetes
  • Lexicon Pharmaceuticals, Inc.